French court rules against Sanofi in land­mark De­pakine case

Sanofi has faced a slew of al­le­ga­tions over the last sev­er­al years that its epilep­sy drug De­pakine caus­es birth de­fects when tak­en dur­ing preg­nan­cy. Last week, it suf­fered a sting­ing loss in a French court — but the phar­ma gi­ant’s le­gal trou­ble is far from over.

A court in Nan­terre — a city sev­er­al miles out­side of Paris — ruled last week that Sanofi must pay up to €450,000 in dam­ages to a fam­i­ly whose child suf­fered a form of autism af­ter ex­po­sure to De­pakine, mul­ti­ple sources re­port­ed. Ac­cord­ing to Reuters, plain­tiffs al­leged that Sanofi knew of the po­ten­tial risks to preg­nant women, and failed to no­ti­fy pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.